Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 11 years of Non-Current Debt data on file, last reported at $340.3 million in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 188.4% year-over-year to $340.3 million in Q1 2026; TTM through Mar 2026 was $340.3 million, a 188.4% increase from a year earlier, with the FY2025 full-year figure at $339.9 million, up 189.09% from the prior year.
• Non-Current Debt for Q1 2026 stood at $340.3 million, roughly flat from $339.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for MDGL reached as high as $340.3 million in Q1 2026 and fell as low as $48.7 million in Q2 2022.
• Historically, Non-Current Debt has averaged $146.8 million across 5 years, with a median of $116.8 million in 2024.
• Across the five-year window, Non-Current Debt surged 203.96% in 2023 and dropped 21.36% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $49.3 million in 2022, then jumped by 134.29% to $115.5 million in 2023, then gained by 1.81% to $117.6 million in 2024, then surged by 189.09% to $339.9 million in 2025, then gained by 0.13% to $340.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $340.3 million in Q1 2026, $339.9 million in Q4 2025, and $339.8 million in Q3 2025.